Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares were down 1.5% on Friday . The stock traded as low as GBX 4.80 ($0.06) and last traded at GBX 4.83 ($0.06). Approximately 678,168 shares traded hands during trading, a decline of 82% from the average daily volume of 3,870,123 shares. The stock had previously closed at GBX 4.90 ($0.06).
Wall Street Analyst Weigh In
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
Check Out Our Latest Stock Analysis on POLB
Poolbeg Pharma Stock Performance
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- Insider Trades May Not Tell You What You Think
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- What is the Shanghai Stock Exchange Composite Index?
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
